CN101507822B - 皮肤瘢痕形成的减少 - Google Patents

皮肤瘢痕形成的减少 Download PDF

Info

Publication number
CN101507822B
CN101507822B CN2009101287188A CN200910128718A CN101507822B CN 101507822 B CN101507822 B CN 101507822B CN 2009101287188 A CN2009101287188 A CN 2009101287188A CN 200910128718 A CN200910128718 A CN 200910128718A CN 101507822 B CN101507822 B CN 101507822B
Authority
CN
China
Prior art keywords
rad
waf1
cip1
cell
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009101287188A
Other languages
English (en)
Chinese (zh)
Other versions
CN101507822A (zh
Inventor
D·古
M·泽佩达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of CN101507822A publication Critical patent/CN101507822A/zh
Application granted granted Critical
Publication of CN101507822B publication Critical patent/CN101507822B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2009101287188A 2003-11-24 2004-11-23 皮肤瘢痕形成的减少 Expired - Fee Related CN101507822B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52499303P 2003-11-24 2003-11-24
US60/524993 2003-11-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800406132A Division CN100482674C (zh) 2003-11-24 2004-11-23 皮肤瘢痕形成的减少

Publications (2)

Publication Number Publication Date
CN101507822A CN101507822A (zh) 2009-08-19
CN101507822B true CN101507822B (zh) 2012-06-06

Family

ID=34632948

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009101287188A Expired - Fee Related CN101507822B (zh) 2003-11-24 2004-11-23 皮肤瘢痕形成的减少
CNB2004800406132A Expired - Fee Related CN100482674C (zh) 2003-11-24 2004-11-23 皮肤瘢痕形成的减少

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004800406132A Expired - Fee Related CN100482674C (zh) 2003-11-24 2004-11-23 皮肤瘢痕形成的减少

Country Status (13)

Country Link
US (3) US7465442B2 (enExample)
EP (1) EP1692154A4 (enExample)
JP (2) JP4842139B2 (enExample)
KR (1) KR101167330B1 (enExample)
CN (2) CN101507822B (enExample)
AU (1) AU2004293474B2 (enExample)
BR (1) BRPI0416920A (enExample)
CA (1) CA2546287C (enExample)
IL (1) IL175603A (enExample)
NO (1) NO20062978L (enExample)
NZ (1) NZ546983A (enExample)
WO (1) WO2005051971A1 (enExample)
ZA (1) ZA200604147B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1692154A4 (en) * 2003-11-24 2009-07-08 Canji Inc REDUCTION OF SKIN TEMPERING
CN103271761B (zh) 2008-01-14 2015-10-28 康文图斯整形外科公司 用于骨折修补的装置和方法
CA2753338A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US20110178520A1 (en) 2010-01-15 2011-07-21 Kyle Taylor Rotary-rigid orthopaedic rod
AU2011207550B2 (en) 2010-01-20 2016-03-10 Conventus Orthopaedics, Inc. Apparatus and methods for bone access and cavity preparation
CN105361942B (zh) 2010-03-08 2018-01-09 康文图斯整形外科公司 用于固定骨植入物的装置及方法
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
JP6883987B2 (ja) * 2013-12-04 2021-06-09 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
CN105939677A (zh) 2013-12-12 2016-09-14 康文图斯整形外科公司 组织移位工具和方法
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CA3021073A1 (en) * 2016-04-14 2017-10-19 Trizell Ltd. Viral vector stabilization
US10918426B2 (en) 2017-07-04 2021-02-16 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111304A1 (en) * 2000-12-01 2002-08-15 Andrius Kazlauskas Methods and compositions for treating fibrotic diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4505266A (en) 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
WO1992002247A1 (en) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Method for treating corneal endothelial wounds
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
ATE242806T1 (de) 1992-10-16 2003-06-15 Cold Spring Harbor Lab Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FI955416A7 (fi) 1994-03-18 1996-01-09 Myriad Genetics Inc MTS-geenin sukusolulinjan mutaatioita ja menetelmä syövälle altistumis en löytämiseksi MTS-geenistä
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996012506A1 (en) 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
WO1996019244A1 (en) 1994-12-22 1996-06-27 The University Of North Carolina At Chapel Hill DNA ENCODING A 20 Kd CDK6 INHIBITING PROTEIN
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
AU724324B2 (en) 1995-07-17 2000-09-14 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU1837197A (en) * 1996-01-26 1997-08-20 United States of America, represented by the Secretary, Department of Health and Human Services, The National Institutes of Health, The Hydroxylamine compositions for the prevention or retardation of cataracts
CA2251078A1 (en) 1996-04-10 1997-10-16 The University Of Southern California Gene therapy for proliferative vitreoretinopathy
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
JPH11205102A (ja) 1998-01-13 1999-07-30 Mitsubishi Electric Corp 遅延同期回路
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2001013960A1 (en) * 1999-08-20 2001-03-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for in vivo gene delivery to sites of cartilage damage
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1692154A4 (en) * 2003-11-24 2009-07-08 Canji Inc REDUCTION OF SKIN TEMPERING
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111304A1 (en) * 2000-12-01 2002-08-15 Andrius Kazlauskas Methods and compositions for treating fibrotic diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Todd W . Perkins 等.Adenovirus-mediated gene therapy using humanp21waf-1/cip-1 to prevent wound healing in a rabbit model ofglaucoma filtration surgery.《ARCH OPHTHALMOL120》.2002,第120卷941-949页. *

Also Published As

Publication number Publication date
AU2004293474B2 (en) 2010-12-23
US20050271623A1 (en) 2005-12-08
IL175603A0 (en) 2006-09-05
NO20062978L (no) 2006-06-26
AU2004293474A1 (en) 2005-06-09
ZA200604147B (en) 2007-11-28
US20110129534A1 (en) 2011-06-02
EP1692154A1 (en) 2006-08-23
EP1692154A4 (en) 2009-07-08
US20090142397A1 (en) 2009-06-04
BRPI0416920A (pt) 2007-01-23
JP2007512377A (ja) 2007-05-17
CA2546287C (en) 2014-04-22
CA2546287A1 (en) 2005-06-09
KR20060127414A (ko) 2006-12-12
CN101507822A (zh) 2009-08-19
US8329671B2 (en) 2012-12-11
CN1906205A (zh) 2007-01-31
JP2011207912A (ja) 2011-10-20
CN100482674C (zh) 2009-04-29
WO2005051971A1 (en) 2005-06-09
KR101167330B1 (ko) 2012-07-23
NZ546983A (en) 2009-05-31
US7465442B2 (en) 2008-12-16
JP4842139B2 (ja) 2011-12-21
IL175603A (en) 2011-02-28

Similar Documents

Publication Publication Date Title
US20240000968A1 (en) Mesothelioma Gene Therapy
US8329671B2 (en) Reduction of dermal scarring
JPH10503361A (ja) 組換えｐ５３アデノウイルス方法と組成物
US6982148B2 (en) Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis
MXPA06005826A (en) Reduction of dermal scarring
HK1095525B (en) Methods and compositions for treatment of interferon-resistant tumors
HK1155956A (en) Methods and compositions for treatment of interferon-resistant tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120606

Termination date: 20161123